Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone for Placebo Assessment in Spine Injections
NCT06666621Phase 4Recruiting
- Sponsor
- Middle Tennessee Research Institute
- Start
- Aug 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of naloxone in low back pain (LBP) and facet joint osteoarthritis, sponsored by Middle Tennessee Research Institute. Primary endpoint: Endogenous opioid-dependent placebo analgesia. Started Aug 2024; status: recruiting.
02
Drugs
naloxone
03
Conditions
low back pain (LBP)facet joint osteoarthritis
Beyond the preview
Go deeper on NCT06666621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666621.